Feasibility Study of an Intervention Therapeutic Education for Patients Treated With Androgen Deprivation

The purpose of the study is to build and assess the feasibility of a therapeutic education program, constructed in collaboration with the urologists of the University Hospital of Saint Etienne. The aim of this therapeutic education program is to delay the onset or to reduce the amplitude of the development of insulin resistance and side effects of androgen deprivation therapy in patients treated with androgen deprivation in the context of an evolutive prostate cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Behavior Empowerment Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Social Behavior Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

CHU Saint-Etienne, Saint-Etienne, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients supported in consultation Urology at the University Hospital North Saint Etienne.
Aged over 18 years
Having an evolutive prostate cancer
Patient treated with LHRH agonist for at least 6 months - Affiliated with the national health insurance system
And having completed the worksheet informed consent to participate in the program.

Exclusion criteria

Refusal of participation, protected or under guardianship patients.
Patients unable to understand the study or unable to follow the educational sessions.
Patient (s) with documented cognitive or psychiatric history.
Geographical remotness (more than 100 Kms.)

Treatment and study plan

therapeutic education program

Behavioral

Primary outcomes

Number of patients who refused to participate

Time frame: 6 months

Secondary outcomes

Number of patients in all sessions

Time frame: 6 months
Number of withdrawals

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Institut de Cancérologie de la Loire

Other

Registry information

Acronym: Nutriprophy

Important dates

Study start: 2014
Primary completion: 2014
Study completion: 2014
First posted: Jun 2, 2015
Registry last updated: Jun 2, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed